Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established ...
Our immune system relies on T cells to fight infections. But T cells don't just show up and react—first, they train, get a ...
Researchers hope to undertake clinical studies in multiple cancers, including ovarian cancer, glioblastoma, and others.
Fred Hutch Cancer Center scientists have developed an experimental strategy to give genetically engineered CAR T cells help ...
MB-105, a CD5-targeted CAR-T cell therapy, is being evaluated in a phase 2 trial for relapsed or refractory CD5-positive T-cell lymphoma. The trial, led by Dr. Swaminathan P. Iyer, will assess ...
The Journal of Clinical Oncology podcast, hosted by Dr. Davide Soldato, presents analyses and discussions centered on the latest findings published in ASCO’s esteemed Journal of Clinical Oncology.
Data demonstrate efficacy and durability of vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy, are on par with autologous CAR-T cell therapies in the confirmatory cohort (N=22) and with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results